DEX Immunotherapy and Surgery: Synergy That Redefines Modern Cancer Treatment

Cancer represents one of the most complex medical challenges of our time. Over the decades, standard approaches have included the combination of surgery, chemotherapy, and radiotherapy. While effective in many cases, these strategies have significant limitations, particularly when time becomes a critical factor [1]. One of the most controversial areas in modern oncology is the decision to delay surgery in certain cancers, such as colon, breast, and other solid tumors, in favor of prolonged neoadjuvant chemotherapy [2]. This strategy, designed to reduce tumor size and target micrometastases, can, in some cases, weaken the patient and postpone surgical intervention, which might otherwise have had a significant impact on early reduction of total tumor burden.